Newswire

PRAC Reviews Depression and Anxiety Medicine Deanxit

Meeting room with pharmaceutical professionals

The Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a review of Deanxit, a fixed-dose combination medicine used for treating depression and anxiety. This review is part of the committee’s ongoing efforts to assess the safety and efficacy of medicinal products. The agenda for the PRAC meeting held from 26 to 29 October 2026 includes discussions on various ongoing referrals, including those for flupentixol/melitracen-containing products and parenteral iron-containing products.

This review could have implications for manufacturers and suppliers of Deanxit and similar medications, as any findings may influence regulatory decisions and market access. Stakeholders should monitor the outcomes of this review closely, as it may affect prescribing practices and patient access to these therapies.

Source: ema.europa.eu · Image: Visit of a delegation from the European Federation of Pharmaceutical Industries and Associations (EFPIA) , to the European Commission (P-066111-00-10) by Europäische Kommission – Audiovisueller Dienst, Christophe Licoppe, Yügen, CE – , CC BY 4.0, via Wikimedia Commons

Explore deeper: the API & FDF Intelligence database is more than a directory. It combines global coverage of APIs, excipients, and finished dosage forms with real market intelligence. You’ll find: – Price ranges for APIs, excipients, and formulations. – DMF, CEP, and GMP compliance status. – Manufacturer portfolios by product and geography. – Direct contacts for every producer and FDF holder, ready for outreach. Instead of scattered spreadsheets and endless searches, the entire picture is a few clicks away. Subscription starts at an accessible rate — see how much time and budget you save by centralizing everything.
Start your 7-day trial and see what the database can do →

Explore Related Stories